| 2022-11-09 |
复牌提示：
2022-11-09 07:55:02 停牌，复牌日期 2022-11-09 08:45:00
|
| 2022-11-09 |
详情>>
股本变动：
变动后总股本14495.53万股
|
| 2022-11-09 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-1.32美元,归母净利润-1.88亿美元,同比去年增长6.30%
|
| 2022-11-01 |
详情>>
内部人交易：
Harding Thomas C.等共交易20笔
|
| 2022-08-08 |
详情>>
业绩披露：
2022年中报每股收益-0.93美元,归母净利润-1.31亿美元,同比去年增长0.92%
|
| 2022-08-08 |
财报披露：
美东时间 2022-08-08 盘前发布财报
|
| 2022-05-05 |
详情>>
业绩披露：
2022年一季报每股收益-0.44美元,归母净利润-6016.9万美元,同比去年增长9.22%
|
| 2022-04-27 |
股东大会：
将于2022-06-09召开股东大会
会议内容 ▼▲
- 1.To elect four Class II directors for a three-year term;
2.To approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio of 1-for-7 (the “Reverse Stock Split”);
3.To approve an amendment to our Amended and Restated Certificate of Incorporation to decrease, concurrent with and conditioned upon the implementation of the Reverse Stock Split, the number of authorized shares of our common stock from 200,000,000 to 57,142,000 shares;
4.To approve an amendment and restatement of the Clovis Oncology, Inc. Amended and Restated 2020 Stock Incentive Plan to increase the number of shares of common stock available for issuance under the Plan by 4,000,000 shares (prior to giving effect to the Reverse Stock Split), concurrent with and conditioned upon the implementation of the Reverse Stock Split;
5.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statement;
6.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
7.To approve the adjournment of the Annual Meeting, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of Proposal 2, Proposal 3 or Proposal 4;
8.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2022-02-24 |
详情>>
业绩披露：
2021年年报每股收益-2.29美元,归母净利润-2.65亿美元,同比去年增长28.35%
|
| 2022-02-24 |
详情>>
业绩披露：
2019年年报每股收益-7.43美元,归母净利润-4亿美元,同比去年增长-8.81%
|
| 2021-11-03 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-1.8美元,归母净利润-2亿美元,同比去年增长25.95%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-04 |
详情>>
业绩披露：
2021年中报每股收益-1.25美元,归母净利润-1.33亿美元,同比去年增长30.72%
|
| 2021-08-04 |
详情>>
业绩披露：
2020年中报每股收益-2.52美元,归母净利润-1.92亿美元,同比去年增长7.38%
|
| 2021-05-05 |
详情>>
业绩披露：
2021年一季报每股收益-0.64美元,归母净利润-6627.7万美元,同比去年增长33.28%
|
| 2021-04-28 |
股东大会：
将于2021-06-10召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors for a three-year term;
2.To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from 200,000,000 to 250,000,000;
3.To approve an amendment and restatement of the Clovis Oncology, Inc. 2020 Stock Incentive Plan to increase the number of shares available for issuance under the Plan;
4.To approve the Clovis Oncology, Inc. 2021 Employee Stock Purchase Plan;
5.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statement;
6.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
7.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2021-02-25 |
详情>>
业绩披露：
2020年年报每股收益-4.38美元,归母净利润-3.69亿美元,同比去年增长7.79%
|
| 2020-11-05 |
详情>>
业绩披露：
2020年三季报(累计)每股收益-3.37美元,归母净利润-2.7亿美元,同比去年增长10.19%
|
| 2020-04-24 |
股东大会：
将于2020-06-04召开股东大会
会议内容 ▼▲
- 1. To elect three Class III directors for a three-year term;
2. To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statement;
3. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
4. To approve the Clovis Oncology, Inc. 2020 Stock Incentive Plan;
5. To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2019-04-26 |
股东大会：
将于2019-06-06召开股东大会
会议内容 ▼▲
- 1.To elect four Class II directors for a three-year term;
2.To approve an amendment to our Amended and Restated Certificate of Incorporation to increase our authorized number of shares of common stock from 100,000,000 to 200,000,000;
3.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statement;
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
5.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2018-04-27 |
股东大会：
将于2018-06-07召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors for a three year term;
2.To consider and vote upon the approval and ratification of our Non-Employee Director Compensation Policy;
3.To consider and vote upon, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statement, including under the heading “Compensation Discussion and Analysis” and the “Summary Compensation Table,” as well as other related tables and disclosure;
4.To consider and vote upon, on an advisory basis, the preferred frequency of the stockholder advisory vote on the compensation of our named executive officers;
5.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
6.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2017-04-26 |
股东大会：
将于2017-06-08召开股东大会
会议内容 ▼▲
- 1. To elect three Class III directors for a three year term;
2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3. To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2016-04-27 |
股东大会：
将于2016-06-09召开股东大会
会议内容 ▼▲
- 1. To elect three Class II directors for a three year term;
2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
3. To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2015-04-30 |
股东大会：
将于2015-06-11召开股东大会
会议内容 ▼▲
- 1. To elect three Class I directors for a three year term;
2. To consider and vote upon, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statement, including under the heading “Compensation Discussion and Analysis” and the “Summary Compensation Table,” as well as other related tables and disclosure;
3. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015;
4. To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2014-04-30 |
股东大会：
将于2014-06-12召开股东大会
会议内容 ▼▲
- 1. To elect three Class III directors for a three year term;
2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014;
3. To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2013-04-29 |
股东大会：
将于2013-06-13召开股东大会
会议内容 ▼▲
- 1. To elect three Class II directors for a three year term;
2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2013;
3. To transact such other business as may properly come before the meeting or any adjournment thereof.
|